title: Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells.
abstract: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been widely used after autologous peripheral blood stem cell transplant (APBSCT) in an attempt to reduce the duration of neutropenia, but whether this treatment has any influence on long-term engraftment remains unknown. We have retrospectively analyzed data from breast cancer patients to compare post-APBSCT rhG-CSF administration in terms of the short-term benefit and myeloid marrow regeneration after 1 year. Group A included 10 patients not treated with post-APBSCT rhG-CSF, while groups B and C comprised 15 and 13 patients treated with this drug from days +1 and +6, respectively. No differences among the three groups were found in age, diagnosis, previous chemo-radiotherapy, CD34+/CD71- cell concentration in pre-transplant bone marrow (BM), mobilization schedule, CD34+ cell yield, conditioning regimen and post-transplant radiotherapy. Post-APBSCT rhG-CSF was shown to accelerate neutrophil recovery, but there were no significant differences in platelet recovery, transfusion requirements, days of fever, antibiotic administration or inhospital stay. With regard to BM hematopoietic precursors 1 year after APBSCT, significantly lower concentrations of total CD34+ cells, committed CD34+/CD33+ subsets, and more immature CD34+/CD71- cells were found in both groups B and C compared with patients not having received the cytokine (group A). Thus, post-APBSCT rhG-CSF administration does not appear to beneficially affect procedure outcome, and might even impair long-term marrow hematopoiesis.
authors.affiliation: Unit of Hematology and Clinical Oncology, School of Medicine, Hospital General Universitario, Murcia, Spain.
authors.forename: M M
authors.initials: MM
authors.lastname: Osma
authors.forename: F
authors.initials: F
authors.lastname: Ortuño
authors.forename: M L
authors.initials: ML
authors.lastname: Lozano
authors.forename: J
authors.initials: J
authors.lastname: Gomez-Espuch
authors.forename: F
authors.initials: F
authors.lastname: Ayala
authors.forename: I
authors.initials: I
authors.lastname: Sanchez-Serrano
authors.forename: E
authors.initials: E
authors.lastname: Perez-Ceballos
authors.forename: J M
authors.initials: JM
authors.lastname: Moraleda
authors.forename: V
authors.initials: V
authors.lastname: Vicente
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects; D001943:Breast Neoplasms / Q000628:therapy; D002452:Cell Count; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival / Q000187:drug effects; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000494:pharmacology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D008875:Middle Aged; D023461:Myeloid Progenitor Cells / Q000187:drug effects*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D014182:Transplantation, Autologous / Q000379:methods
chemical_list: D015703:Antigens, CD; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor